Introduction
Acute clinical manifestations in patients suffering from atherosclerosis are usually caused by a plaque rupture followed by intraluminal thrombus formation. Unstable plaques that are prone to rupture are characterized by a large lipid core, a thin fibrous cap, intraplaque neovascularization, and a large inflammatory cell infiltrate composed of macrophages, T-cells and mast cells (MCs) . 1 Mast cells are inflammatory cells traditionally known for their role in allergy and in innate immune responses. 2 Mast cells are filled with cytoplasmic secretory granules, which they exocytose upon activation. Such activated MCs are particularly abundant at the sites of atheromatous erosion or rupture in patients who have died of myocardial infarction. 3 More recently, animal experiments have demonstrated that MCs are also actively involved in the initiation and progression of atherosclerotic disease. For example, more unstable atherosclerotic lesions were observed in ApoE 2/2 mice treated with MC activators. 4, 5 This unfavourable phenotype of plaque destabilization could be prevented by treatment with a MC stabilizer such as sodium cromolyn 4 or tranilast. 6 In line with these data, it was observed that MC-deficient mice were demonstrated to develop smaller lesions with a more stable phenotype. 7 -9 One of the proposed mechanisms by which MCs may render the plaques unstable is their ability to induce neovascularization under normal and pathological conditions. 10 Importantly, in autopsy studies it has been observed that MCs accumulate in neovessel-rich areas of atherosclerotic plaques. 11 -14 Moreover, it was demonstrated that the MCs situated near the newly formed vessels contained basic fibroblast growth factor, a potent pro-angiogenic factor. 15 These data suggest that MCs are involved in the formation of microvessels in the atherosclerotic plaque and so accelerate plaque progression into an unstable plaque phenotype.
We recently showed that intraplaque neovascularization and intraplaque haemorrhage (IPH) in carotid plaques are predictive for cardiovascular events elsewhere in the human body. 16 This underscores the need for improved understanding how intraplaque neovascularization renders atherosclerotic plaques prone to trigger atherothrombotic events in the atherosclerosis-prone segments of the arterial tree. Although it is known that the accumulation of inflammatory cells into the plaque largely contributes to the process of plaque destabilization, the size of the athero-express bank allows the identification of inflammatory cell types that are independently associated with intraplaque neovascularization. In the present study, we thus aimed to examine the association of local MC numbers with local plaque characteristics, such as plaque neovascularization, in a large number of human samples. As an association between local MCs and future cardiovascular events has not been investigated previously, we related plaque MC numbers with the occurrence of future cardiovascular events.
Materials and methods

Study population and design
The Athero-express is an ongoing longitudinal study in two Dutch teaching hospitals in Utrecht and Nieuwegein, the Netherlands. 17 In this study, a total of 270 patients of the Athero-express biobank, undergoing carotid endarterectomy (CEA) were included. Indication for CEA was based on recommendations by the Asymptomatic Carotid Atherosclerosis Study and Asymptomatic Carotid Surgery Trial studies for asymptomatic patients and the North American Symptomatic Carotid Endarterectomy Trial and European Carotid Surgery Trial studies for symptomatic patients. 18 -20 All the indications were reviewed in a multidisciplinary vascular team, and all the patients were evaluated by a neurologist before CEA to assess their neurological status and document the preoperative symptoms. We selected patients who remained healthy and patients who suffered from an event during the follow-up in a 2:1 ratio. These patients were randomly selected among those who had been operated between March 2002 and December 2007. The local medical ethical boards of both participating hospitals approved the studies. All participating patients signed a written informed consent prior to inclusion. Of all the patients, the baseline characteristics, medication use, and medical history were obtained via questionnaires and the patients' medical records.
Follow-up
After CEA patients were followed up to 3 years by questionnaire. Primary outcome is defined as any cardiovascular event including (non-) fatal stroke, (non-) fatal myocardial infarction, sudden death, other vascular death, and any arterial vascular intervention that had not been planned at the time of inclusion (e.g. carotid surgery or angioplasty, coronary artery bypass, percutaneous coronary artery intervention, peripheral vascular surgery or angioplasty). Endpoints were validated by two members of the outcome assessment committee. If no consensus was reached, a third observer was consulted for the final judgment of the endpoint.
Materials
A total of 270 patients that underwent CEA were randomly selected for the present study with a ratio of 2:1 for control patients vs. patients who suffered from an event during the follow-up. Six patients were excluded from the study as the endarterectomy specimens were unsuitable for histological analysis, resulting in a total of 264 patients (events n ¼ 89, controls n ¼ 175). The carotid plaques used in this study were processed as described previously. 17 In short, after surgical dissection the plaque was cut into segments of 5 mm. The segment with the largest plaque area was fixed in formalin and embedded in paraffin for histology. The two adjacent sections were frozen in liquid nitrogen and used for protein isolation. In addition, blood was drawn prior to the CEA procedure, and plasma was stored at 2808C.
Immunohistochemistry
To assess MC numbers in the atherosclerotic specimens, plaque sections were pre-treated with pepsin buffer for 15 min at 378C. A monoclonal mouse antibody against MC tryptase (dilution 1:400, Dako-Cytomation, Carpinteria, CA, USA) was used to stain MCs. Powervision poly HRP against mouse IgG (ImmunoLogic, Duiven, The Netherlands) was used as secondary antibody after which the tryptase staining was visualized with diaminobenzidine. Sections were counterstained with Haematoxylin. Total MC numbers were determined by counting all MCs present in a plaque cross-section at ×40 magnification. A subset was analysed by another independent researcher to assess intra-observer variability (Spearman correlation coefficient r ¼ 0.947; P , 0.001). In 100 randomly chosen plaques, the number of degranulating MCs was determined. A degranulating MC was defined by a group of MC tryptase-positive extracellular granules in close proximity of each other or in close proximity of an MC. The percentage of degranulating MCs was assessed by counting the first 50 MCs observed by the researcher. This percentage was extrapolated to the total number of degranulating MCs per plaque section. The total plaque area (mm 2 ) was measured using the analySIS 2.8 software (Olympus Soft Imaging Solutions GmbH, Münster, Germany) to determine the distribution density of MCs expressed as numbers of MC/mm 2 .
Consecutive sections were also stained for CD68 (macrophages), CD66 (neutrophils), and CD34 (endothelial cells). The Image-analysing software (Soft Imaging Solutions GmbH, Münster, Germany) was used to determine positive macrophage staining expressed as a percentage of the covered plaque area 17 and to assess total neutrophil numbers.
Microvessels were counted at three sites with most prevalent CD34 S. Willems et al.
staining within the section (hotspots) and were expressed as average microvessel density per hotspot. 16 The presence of IPH was assessed with Haematoxylin and Eosin (H&E) staining and fibrin (Mallory's phosphotungstic acid-haematoxylin). The size of the extracellular lipid core (atheroma) was assessed by the H&E and picrosirius red stain. 17 The overall plaque phenotype was based on the percentage of confluent lipid areas of the total plaque area that were visually estimated (fibrous: ,10% fat; fibroatheromatous: 10 -40%; atheromatous: .40% fat).
For the double immunostaining of MCs and vessels pepsin pre-treated sections were incubated with the mouse anti-MC tryptase antibody (1:400) followed by Brightvision poly AP-anti-Mouse IgG (Immunologic) incubation and development with Liquid permanent red (DAKO, Glostrup, Denmark). Subsequently sections were boiled in citrate buffer, pH 6.0, incubated with a monoclonal mouse anti CD34 antibody (1:400; Immunotech, Marseille, France) followed by incubation with Brightvision poly AP-anti-Mouse IgG and developed with the alkaline phosphatase substrate kit III (Vector Labs, Burlingame, CA, USA). For the double immunostaining, no nuclear staining was used.
Quantification of mast cell tryptase levels in patient plasma
Plasma obtained before surgery was available from 135 (events n ¼ 52, controls n ¼ 83) of the selected patients. Baseline characteristics did not differ between these patients and the total group of studied patients (data not shown). Mast cell tryptase levels were determined in citrate plasma samples using an ImmunoCAPw 250 tryptase assay (Phadia AB, Uppsala, Sweden).
Quantification of RANTES, Eotaxin-1, monocyte chemotactic protein-1, and transforming growth factor-b1
Protein isolation on the adjacent segments to the culprit lesions was performed by a standardized method. In short, the segments were grinded in liquid nitrogen and dissolved in Tripure or Tris (Roche). Total protein concentration of each sample was quantified. Levels of monocyte chemotactic protein-1 (MCP-1), CCL-5 (RANTES), and CCL-11 (Eotaxin) were measured by the Multiplex Immunoassay (Bioplex, Biorad Laboratories, Hercules, USA) in tripure protein isolates. Transforming growth factor-b1 (TGF-b1) expression was quantified in Tris isolates by the Quantikine Human TGF-b1 Immunoassay (R&D Systems, Wiesbaden, Germany). Protein levels for all four chemoattractants were corrected for a total amount of protein within the segment.
Statistics and data analysis SPSS 20 was used for all analyses (SPSS, Inc., Chicago, IL, USA). Mast cell numbers are not normally distributed; non-parametrical testing was used to determine differences. The Mann-Whitney U test was used to obtain differences in MC numbers as a continuous variable for all common risk factors. For multiple groups testing, the Kruskal -Wallis test was used. The Spearman correlation coefficient was used to calculate relations of (degranulating) MC/mm 2 or tryptase plasma levels with all continuous variables in this study. Differences were considered significant with a twosided P-value of ,0.05. The receiver-operating characteristic (ROC) curve was used to determine the optimal cut-off value to divide the patients in two groups with low and high MC/mm 2 . To determine the prognostic value of intraplaque MC/mm 2 , the Cox-regression model was used. A multivariate analysis was performed to adjust for confounders. On the basis of the previous reports, 4, 6 we expected the number of MCs to associate with plaque vulnerability and increased risk for future cardiovascular events.
Results
Baseline characteristics Table 1 depicts baseline clinical characteristics for the patients included in this study. The patient population represents a typical population of patients with vascular occlusive diseases. The mean age of the patients was 68, with a preponderance of males (71%). Moreover, the majority of patients was symptomatic (81%), suffered from hypertension (88%) and used statins (73%).
Mast cells and plaque characteristics
Mast cells were found to be distributed throughout the entire plaque. They were more abundantly present in the areas where also microvessels were present ( Figure 1C ) , i.e. in the deep layers of the plaque at the interface of the media ( Figure 1A) . In more unstable lesions, MC accumulations were also found in the shoulders of the plaques ( Figure 1B) . The median number of total MCs present was 108 (55 -233) cells per plaque section ( 
Mast cells and intraplaque neovascularization
A strong significant correlation between MCs and intraplaque microvessel density was observed. A 2.4-fold increase in MC/mm 2 was observed comparing the first and fourth quartile of counted plaque microvessels ( Figure 2 ). In addition, also on a continuous scale, microvessel density correlated significantly with total MC numbers (r ¼ 0.416, P , 0.001; Table 2 ). A positive correlation with microvessel density was also observed for neutrophils and macrophages (r ¼ 0.128, P ¼ 0.045 and r ¼ 0.133, P , 0.001, respectively, data not shown). Therefore, we examined whether a more general pan-inflammatory process would explain the observed association between MCs and microvessel density. In Figure 3 , the average microvessel density is provided for four groups based on high or low amounts of MCs and macrophages (A) or MC and neutrophil numbers (B) using the median as a cut-off value. Plaques with high microvessel density were characterized by high MC numbers. controlled for MC numbers. Plaques characterized by a high abundance of both cell types did show a higher microvessel density. Similar results were observed for neutrophils. Plasma tryptase levels correlated with the number of MCs and degranulating MC/mm 2 plaque (r ¼ 0.243, P ¼ 0.004 and r ¼ 0.363, P ¼ 0.001, respectively), but were not associated with microvessel density. Furthermore, no correlation was found between the number of degranulating MC/mm 2 and microvessel density.
In addition, no association was observed for MCs and plaque protein levels of the MC chemoattractants RANTES (r ¼ 20.041, P ¼ 0.597), Eotaxin (r ¼ 0.126, P ¼ 0.100), TGF-b1 (r ¼ 0.089, P ¼ 0.239), or MCP-1 (r ¼ 0.044, P ¼ 0.564). In contrast, a positive correlation was observed between macrophage numbers and MCP-1 or RANTES plaque protein levels (r ¼ 0.138, P ¼ 0.001 and r ¼ 0.107, P ¼ 0.008, respectively).
Mast cells and clinically relevant characteristics
Patients entering the study with symptoms as amaurosis fugax, transient ischaemic attack, and stroke contained significantly more MCs in their plaques compared with asymptomatic patients [3. inflammatory co-morbidities and anti-inflammatory drug use, did not affect the relation of MCs and primary outcome. In addition, higher tryptase plasma levels were observed in patients that had a secondary event [52 events out of 135 patients, 5.3 (4.2 -6.9) vs. 4.5 (3.7 -5.8) mg/mL, P ¼ 0.046, Figure 4 ].
Discussion
Atherosclerosis is a chronic inflammatory disorder where numerous inflammatory cell types are known to be involved. Such cells can enter the plaque from the circulation through the endothelium and create an inflammatory environment in the vessel wall. A characteristic of a rupture-prone plaque that has gained attention of the scientific community is the presence of intraplaque vessels. In this study, we show that MCs associate with microvessel density in the plaque. It is known that not only MCs, but also other inflammatory cells, are capable of inducing new vessel formation, 21 suggesting that an overall inflammatory environment is responsible for the formation of the neovessels in the plaque. We also observed that, besides MCs, macrophages, and neutrophils are associated with microvessel density. However, this study provides a sufficient sample size to show that the association between microvessel density and MCs is significant and independent of the presence of other inflammatory cell types. Particularly interesting is the finding that high MC numbers in the plaque were associated with a higher average microvessel density independent of the amount of macrophages and neutrophils. These data suggest that MCs might be important for plaque neovascularization. Nevertheless, when all cell types are present an even higher microvessel density is observed.
A possible explanation might be that, as the plaque progresses, the number of inflammatory cells increases due to increased 23 We confirm these observations in our patient cohort where we also noticed more MC in the plaques of symptomatic patients compared with asymptomatic patients. The impact of MCs on atherosclerotic plaque progression has long been underestimated, as it was considered that MCs were only present in low numbers. Therefore, another important finding in this study is that MCs are highly prevalent in the atherosclerotic lesion: in some of the plaques total MC numbers of 800 cells per section were detected, with an overall median of just .100 cells per section. Plaques often showed confluency of CD68-positive foam cells. The percentage of macrophages is, therefore, depicted as percentage of the covered area, because it was not always possible to quantify the individual cells. This makes comparison of absolute macrophage and MC numbers difficult in our cohort. It is though acknowledged that macrophages by far outnumber all other cell types in the advanced atherosclerotic plaques. 23 Nevertheless, together with experimental data in the literature, our data suggest that the MC is a prominent inflammatory cell type accumulating in the atherosclerotic plaque during plaque progression. We considered that particularly degranulating MCs would be responsible for inducing intraplaque neovascularization as they are frequently observed near the microvessels. 11, 15, 24, 25 However, we could not observe an association between degranulating MC numbers and microvessel density. Also, no association was observed between degranulating MCs and any of the other rupture-prone characteristics or future events. This might suggest that the induction of new vessel formation is more related to a regulated nonexocytotic release of pro-angiogenic growth factors rather than to the extent of an exocytotic release of countable granules, i.e. degranulation of activated MCs. 26 In this study, we show that MC presence is associated with thrombus formation and IPH. It was hypothesized that MC components can induce hyperpermeability or erosion of endothelial cells of the microvessels in the plaques eventually leading to IPH or thrombus formation. 3, 27 This is in accordance with the most important finding in our study, that plaque MC numbers associated independently with future cardiovascular events. In contrast, in the study of Hellings et al. 16 showing that microvessel density is also predictive for future events, neither macrophage nor neutrophil numbers were found to associate with the occurrence of secondary manifestations. Interestingly, we also observed higher plasma tryptase levels in patients that experienced a secondary event. The tryptase levels correlated positively with the number of (degranulating) MCs in the plaque, implying that the presence of degranulating, i.e. tryptasesecreting MCs in a plaque is not only responsible for the local matrix degradation, but also representative for the systemic changes that might be responsible for the secondary manifestations. The correlation of intraplaque MC numbers with future events has never been reported previously; however, MC tryptase plasma levels have been tested as a possible biomarker for cardiovascular disease. Thus, in agreement with our data, elevated tryptase levels were observed in patients with substantial coronary heart disease with the highest levels in the subgroup with acute myocardial infarction. 28 In addition, higher MC tryptase levels were observed in patients with significant coronary artery disease (CAD) defined by stenosis of over 50%. 29 Moreover, in another study of the group of Deliargyris, tryptase levels were elevated in patients with CAD. 30 Conversely, no differences in MC tryptase were observed in patients with acute coronary syndrome. 31, 32 Besides tryptase, several other MC-derived components have also been associated with disease severity, and, in general, most studies underline the importance of MC mediators in inflammatory diseases. Taken together, we show here for the first time that intraplaque MC numbers and plasma MC tryptase associate with future cardiovascular events. However, the results of this clinical proof-of-concept study are not sufficient to suggest utilization of the above observations in a regular clinical setting for prediction studies. Nevertheless, the data do strengthen the hypothesis that the presence of MCs in advanced carotid plaques increases risk for secondary cardiovascular manifestations, possibly by inducing intraplaque neovascularization, and via matrix degradation, which may together increase the incidence of IPH and thrombus formation. However, extensive research is necessary before MC stabilizing agents can be considered as a possible therapeutic opportunity preventing clinical manifestations by plaque stabilization in the future. For example, animal experiments inhibiting MC activation by stabilizing agents should be performed to proof causality between plaque MCs and neovascularization.
In conclusion, we show that MC numbers in the carotid atherosclerotic plaque associate with future cardiovascular events. These data correspond with the strong association found between MC numbers and intraplaque neovascularisation, now evolving as an important characteristic of rupture-prone atherosclerotic lesions, which may trigger acute atherothrombotic complications in the vulnerable patients.
